437 related articles for article (PubMed ID: 18387932)
21. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G
Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351
[TBL] [Abstract][Full Text] [Related]
22. [Correlation of metastasis-free survival in patients with breast cancer and changes in the direction of expression of multidrug resistance genes during neoadjuvant chemotherapy].
Litviakov NV; Garbukov EIu; Slonimskaia EM; Tsyganov MM; Denisov EV; Vtorushin SV; Khristenko KIu; Zav'ialova MV; Cherdyntseva NV
Vopr Onkol; 2013; 59(3):334-40. PubMed ID: 23909034
[TBL] [Abstract][Full Text] [Related]
23. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
[TBL] [Abstract][Full Text] [Related]
24. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
[TBL] [Abstract][Full Text] [Related]
25. Gene expression profile prospectively predicts peritoneal relapse after curative surgery of gastric cancer.
Takeno A; Takemasa I; Seno S; Yamasaki M; Motoori M; Miyata H; Nakajima K; Takiguchi S; Fujiwara Y; Nishida T; Okayama T; Matsubara K; Takenaka Y; Matsuda H; Monden M; Mori M; Doki Y
Ann Surg Oncol; 2010 Apr; 17(4):1033-42. PubMed ID: 20012501
[TBL] [Abstract][Full Text] [Related]
26. Post-treatment tumor gene expression signatures are more predictive of treatment outcomes than baseline signatures in breast cancer.
Lee SC; Xu X; Chng WJ; Watson M; Lim YW; Wong CI; Iau P; Sukri N; Lim SE; Yap HL; Buhari SA; Tan P; Guo J; Chuah B; McLeod HL; Goh BC
Pharmacogenet Genomics; 2009 Nov; 19(11):833-42. PubMed ID: 19809382
[TBL] [Abstract][Full Text] [Related]
27. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.
Anders CK; Hsu DS; Broadwater G; Acharya CR; Foekens JA; Zhang Y; Wang Y; Marcom PK; Marks JR; Febbo PG; Nevins JR; Potti A; Blackwell KL
J Clin Oncol; 2008 Jul; 26(20):3324-30. PubMed ID: 18612148
[TBL] [Abstract][Full Text] [Related]
28. Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia.
Rao AV; Valk PJ; Metzeler KH; Acharya CR; Tuchman SA; Stevenson MM; Rizzieri DA; Delwel R; Buske C; Bohlander SK; Potti A; Löwenberg B
J Clin Oncol; 2009 Nov; 27(33):5580-6. PubMed ID: 19858393
[TBL] [Abstract][Full Text] [Related]
29. Membrane-bound complement regulatory proteins are prognostic factors of operable breast cancer treated with adjuvant trastuzumab: a retrospective study.
Liu M; Yang YJ; Zheng H; Zhong XR; Wang Y; Wang Z; Wang YG; Wang YP
Oncol Rep; 2014 Dec; 32(6):2619-27. PubMed ID: 25241923
[TBL] [Abstract][Full Text] [Related]
30. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling.
Azim HA; Michiels S; Bedard PL; Singhal SK; Criscitiello C; Ignatiadis M; Haibe-Kains B; Piccart MJ; Sotiriou C; Loi S
Clin Cancer Res; 2012 Mar; 18(5):1341-51. PubMed ID: 22261811
[TBL] [Abstract][Full Text] [Related]
31. Gene expression profiling-derived immunohistochemistry signature with high prognostic value in colorectal carcinoma.
Chang W; Gao X; Han Y; Du Y; Liu Q; Wang L; Tan X; Zhang Q; Liu Y; Zhu Y; Yu Y; Fan X; Zhang H; Zhou W; Wang J; Fu C; Cao G
Gut; 2014 Sep; 63(9):1457-67. PubMed ID: 24173294
[TBL] [Abstract][Full Text] [Related]
32. Co-expression of parathyroid hormone related protein and TGF-beta in breast cancer predicts poor survival outcome.
Xu C; Wang Z; Cui R; He H; Lin X; Sheng Y; Zhang H
BMC Cancer; 2015 Nov; 15():925. PubMed ID: 26597083
[TBL] [Abstract][Full Text] [Related]
33. Early response to neo-adjuvant chemotherapy in carcinoma of the breast predicts both successful breast-conserving surgery and decreased risk of ipsilateral breast tumor recurrence.
Ishitobi M; Komoike Y; Motomura K; Koyama H; Inaji H
Breast J; 2010; 16(1):9-13. PubMed ID: 19929889
[TBL] [Abstract][Full Text] [Related]
34. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
35. Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers.
Coutant C; Rouzier R; Qi Y; Lehmann-Che J; Bianchini G; Iwamoto T; Hortobagyi GN; Symmans WF; Uzan S; Andre F; de Thé H; Pusztai L
Clin Cancer Res; 2011 Apr; 17(8):2591-601. PubMed ID: 21248301
[TBL] [Abstract][Full Text] [Related]
36. Prognostic applications of gene expression signatures in breast cancer.
Normanno N; De Luca A; Carotenuto P; Lamura L; Oliva I; D'Alessio A
Oncology; 2009; 77 Suppl 1():2-8. PubMed ID: 20130425
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
38. A functional genomic model for predicting prognosis in idiopathic pulmonary fibrosis.
Huang Y; Ma SF; Vij R; Oldham JM; Herazo-Maya J; Broderick SM; Strek ME; White SR; Hogarth DK; Sandbo NK; Lussier YA; Gibson KF; Kaminski N; Garcia JG; Noth I
BMC Pulm Med; 2015 Nov; 15():147. PubMed ID: 26589497
[TBL] [Abstract][Full Text] [Related]
39. An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer.
Bild AH; Parker JS; Gustafson AM; Acharya CR; Hoadley KA; Anders C; Marcom PK; Carey LA; Potti A; Nevins JR; Perou CM
Breast Cancer Res; 2009; 11(4):R55. PubMed ID: 19638211
[TBL] [Abstract][Full Text] [Related]
40. Fuzzy logic selection as a new reliable tool to identify molecular grade signatures in breast cancer--the INNODIAG study.
Kempowsky-Hamon T; Valle C; Lacroix-Triki M; Hedjazi L; Trouilh L; Lamarre S; Labourdette D; Roger L; Mhamdi L; Dalenc F; Filleron T; Favre G; François JM; Le Lann MV; Anton-Leberre V
BMC Med Genomics; 2015 Feb; 8():3. PubMed ID: 25888889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
